31 completed, 13 recruiting, 6 unknown, 4 active not recruiting. 59 Phase 2, 9 Phase 3, 3 Phase 1.
Follow Long COVID: new trials by email Literature Review of Long COVID trials Research Report on Long COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 30 | 2026-12-30 | 2026-10-16 |
| SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction Valacyclovir, Celecoxib, Paxlovid - Post-acute Sequelae of COVID-19, Long COVID | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 150 | 2026-10-20 | 2026-10-28 |
| Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome VYD2311, Placebo - Long COVID, COVID-19 (SARS-CoV-2 Infection) | Phase 2 | Not yet recruiting | Invivyd, Inc. | 130 | 2026-10-01 | 2026-10-27 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID | Phase 2 | Recruiting | ParagonClinicals Inc. | 82 | 2026-05-20 | 2026-06-04 |
| Immunoadsorption in Autoimmune Long COVID Immunoadsorption, Sham Comparator - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 70 | 2026-01-01 | 2026-01-05 |
| Taurine Supplementation in Long COVID Taurine, Placebo - Long COVID | Phase 2 / Phase 3 | Recruiting | University of Alberta | 300 | 2025-11-18 | 2026-09-18 |
| A Study to Assess Anktiva in Patients With Long Covid-19. N-803 (IL-15 Superagonist) - Long COVID | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-14 | 2026-05-11 |
| The Long COVID Treatment Trial Tirzepatide, Placebo - Long COVID | Phase 2 | Active not recruiting | Scripps Translational Science Institute | 1000 | 2025-10-30 | 2025-12-23 |
| A Study to Examine Anktiva for the Treatment of COVID-19. Anktiva - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | ImmunityBio, Inc. | 40 | 2025-09-04 | 2026-09-24 |
| Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation accelerated intermittent theta burst stimulation - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | University of New Mexico | 60 | 2025-07-07 | 2026-07-15 |
| Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 Ketamine only - Long COVID | Phase 2 | Completed | University of Texas at Austin | 20 | 2025-06-05 | 2026-09-17 |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| NE3107 in Adults With Neurological Symptoms of Long COVID NE3107, Placebo - Long COVID | Phase 2 | Completed | BioVie Inc. | 203 | 2025-04-29 | 2026-09-22 |
| Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) Plitidepsin 1.5 mg/day, Placebo, Placebo and Plitidepsin 1.5mg/day - Post COVID-19 Condition, Long COVID Syndrome | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 90 | 2025-02-07 | 2026-10-08 |
| Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Lumbrokinase - Long Covid, Post-treatment Lyme Disease Syndrome | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2024-10-09 | 2026-03-13 |
| Antiviral Clinical Trial for Long Covid-19 tenofovir disoproxil/emtricitabine, Selzentry, Placebo - Long Covid | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 90 | 2024-10-01 | 2026-03-13 |
| LIFT: Life Improvement Trial Pyridostigmine, Low-Dose Naltrexone, Placebo - ME/CFS, Long COVID | Phase 2 | Recruiting | Brigham and Women's Hospital | 160 | 2024-09-10 | 2026-10-15 |
| RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 361 | 2024-08-12 | 2026-06-03 |
| RECOVER-SLEEP: Platform Protocol Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 830 | 2024-07-31 | 2026-01-22 |
Showing 20 of 59. Sign in to see all of them.
Post-Acute COVID-19 Syndrome (59) · COVID-19 (14) · Fatigue (4) · Mental Fatigue (4) · Parasomnias (3) · Cognitive Dysfunction (2) · Disorders of Excessive Somnolence (2) · Fatigue Syndrome, Chronic (2) · Pulmonary Fibrosis (2) · Anosmia (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronavirus Infections (1) · Depression (1) · Infections (1) · Lyme Disease (1)
Chronic Disease (59) · Coronaviridae Infections (59) · Disease Attributes (59) · Lung Diseases (59) · Nidovirales Infections (59) · Pathologic Processes (59) · Pathological Conditions, Signs and Symptoms (59) · Pneumonia (59) · Pneumonia, Viral (59) · RNA Virus Infections (59) · Respiratory Tract Diseases (59) · Respiratory Tract Infections (59) · Virus Diseases (59) · Coronavirus Infections (58) · Infections (58)
Ritonavir (4) · nirmatrelvir and ritonavir drug combination (3) · ALT-803 (2) · Amantadine (2) · Immunoglobulins, Intravenous (2) · Ivabradine (2) · Maraviroc (2) · Melatonin (2) · Modafinil (2) · Sugars (2) · Taurine (2) · nirmatrelvir (2) · solriamfetol (2) · Atorvastatin (1) · Celecoxib (1)
Kanecia Obie Zimmerman (5) · Duke University (3) · Icahn School of Medicine at Mount Sinai (3) · ImmunityBio, Inc. (2) · University of Alberta (2) · AIM ImmunoTech Inc. (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Bateman Horne Center (1) · Berlin Cures GmbH (1) · BioVie Inc. (1) · Bod Australia (1) · Brigham and Women's Hospital (1) · Cellular Sciences, inc. (1) · Chang Gung Memorial Hospital (1) · Changhai Hospital (1)
United States (38) · Canada (4) · Spain (3) · Brazil (2) · China (2) · Germany (2) · Italy (2) · Austria (1) · Finland (1) · Greece (1) · Netherlands (1) · Norway (1) · Puerto Rico (1) · Sweden (1) · Switzerland (1)
Christina Barkauskas, MD (3) · Cyndya Shibao, MD (3) · Pam Taub, MD (3) · Peter Novak, MD (3) · Susan Redline, MD MPH (3) · Tae Chung, MD (3) · Christopher Grainger, MD (2) · David Putrino, PhD, PT (2) · Lawrence Richer, MD, MSc (2) · Adriana Baltar, PhD (1) · Akiko Iwasaki, PhD (1) · Amy Mathews, M.D. (1) · Andrew I Schamess, MD (1) · Angela M Cheung, MD,PhD (1)
PMID 41720282, PMID 35059791, PMID 38848477, PMID 39356507, PMID 39536121, PMID 40188838, PMID 40810942, PMID 41625963, PMID 42498469, PMID 42673984
2023 (1), 272201800011C-P00005-9999-1 (1), I21RX004409 (1), R01DC021179 (1), UL1TR001412 (1)